Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Risk potential of microbiome management strategies in agroecosystems

ABSTRACT: Risk potential of microbiome management strategies in agroecosystems

PROVIDER: PRJEB61122 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	ERR11191200_1.fastq.gz	Fastqsanger.gz
	ERR11191200_2.fastq.gz	Fastqsanger.gz
	ERR11191400_1.fastq.gz	Fastqsanger.gz
	ERR11191400_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 1101

Similar Datasets

Postoperative risk of IDH mutant glioma-associated seizures and their potential management with IDH mutant inhibitors

Project description:Postoperative risk of IDH mutant glioma-associated seizures and their potential management with IDH mutant inhibitors

| PRJNA947636 | ENA

Genomic reconstruction of Galápagos dog history reveals strategies for management of an invasive species

Project description:Genomic reconstruction of Galápagos dog history reveals strategies for management of an invasive species

| PRJNA1157868 | ENA

A Promising Natural G6PD Inhibitor for Potential Therapeutic Strategies in DLBCL

Project description:A Promising Natural G6PD Inhibitor for Potential Therapeutic Strategies in DLBCL

| PRJNA1070285 | ENA

Differential gene expression in circulating leukocytes from breast cancer patients treated with Cognitive Behavioral Stress Management

Project description:Gene expression profiling was carried out on peripheral blood mononuclear cell mRNA samples collected from 53 female breast cancer patients at 6- or 12-month follow-ups in a randomized controlled trial of Cognitive Behavioral Stress Management or an active control condition. The primary research question is whether gene expression differs in patients treated with Cogntive Behavioral Stress Management vs control conditions. Gene expression profiling was carried out on peripheral blood mononuclear cell mRNA samples collected from 53 female breast cancer patients at 6- or 12-month follow-ups in a randomized controlled trial of Cognitive Behavioral Stress Management or an active control condition. The primary research question is whether gene expression differs in patients treated with Cogntive Behavioral Stress Management vs control conditions. Risk prediction

2012-01-01 | E-GEOD-24079 | biostudies-arrayexpress

A Promising Natural G6PD Inhibitor for Potential Therapeutic Strategies in DLBCL

Project description:Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, has a high degree of clinical and biological heterogeneity. Although most patients can be cured with R-CHOP immunochemotherapy,30-40% of patients have progression or recurrence after treatment. Therefore, there is an urgent need to find new treatments to improve the survival rate of this group of patients. Natural small molecule drugs have unique advantages as anticancer agents due to their low toxicity and multiple targets. This project aims to explore potentially effective natural compounds as new therapeutic strategies for DLBCL. We found that Cinobufagin is a potentially effective therapeutic agent for DLBCL. Glucose 6 phosphate dehydrogenase (G6PD), a risk factor for poor prognosis in DLBCL, was a direct target of Cinobufagin. By inhibiting the enzyme activity of G6PD, Cinobufagin could inhibit DNA synthesis and the production of reductive NADPH, thereby inducing ROS accumulation and apoptosis of DLBCL cells. Our findings provide new strategies for the treatment of DLBCL.

2024-07-31 | GSE254385 | GEO

Alterations in fecal metagenomics and serum metabolomics indicate management strategies for patients with Budd-Chiari syndrome

Project description:OBJECTIVES: We investigated the effects of gut microbiota and serum metabolic levels on the patients with Budd-Chiari syndrome (B-CS), and their guidance for clinical management strategies.DESIGN: 214 B-CS subjects including untreated case (n=93) and treated case (n=121), were enrolled in this study. Gut microbiota and serum metabolome were analyzed using shotgun metagenomics and liquid chromatography mass spectrometry (LC-MS). 41 controls were included.RESULTS: The gut microbiota in B-CS patients showed greater abundance of Campylobacter and lower Saccharomyces, Deinococcus and Thiomonas (P < 0.05). 13 differential metabolites such as taurocholate and (R)−3−Hydroxybutyric acid were identified in B-CS patients. The random forest (RF) models showed that serum metabolome could effectively identify B-CS from healthy controls and RF-metabolomics exhibited perfect discrimination (AUC = 100%, 95% CI: 100% – 100%), which was significantly higher than that achieved by RF-metagenomics (AUC =58.48%, 95% CI: 38.46% – 78.5%). The results of association analysis showed that Campylobacter concisus and taurocholate were significantly positively correlated in B-CS patients with clinical manifestations (P < 0.05). Moreover, Actinobacteria was significantly increased in untreated B-CS patients vs. treated B-CS patients (P < 0.05). Campylobacter and Veillonella were significantly increased in treated B-CS patients vs. health controls (P < 0.05). In addition, Fewer discrepant microbes were found between treated and untreated groups for the patients without clinical manifestation.CONCLUSIONS: We identified major alterations in the gut microbiota and serum metabolome of B-CS patients. Alterations in fecal metagenomics and serum metabolomics guided management strategies for the patients with Budd-Chiari syndrome.

2021-10-20 | MTBLS2319 | MetaboLights

Proteomic-based computational stratification of intermediate-risk prostate cancer patients.

Project description:Gleason grading is an important prognostic indicator for prostate adenocarcinoma and is crucial for patient treatment decisions. However, intermediate-risk patients diagnosed in Gleason Grade Groups (GG) 2 and GG3 can harbour either aggressive or non-aggressive disease, resulting in under- or over-treatment of a significant number of patients. Here, we performed proteomic, differential expression, machine learning, and survival analyses for 1,348 matched tumour and benign samples from 278 patients. Three proteins (F5, TMEM126B and EARS2) were identified as candidate biomarkers in patients with biochemical recurrence. Multivariate Cox regression yielded 18 proteins, from which a risk score was constructed to dichotomise prostate cancer patients into low- and high-risk groups. This 18-protein signature is prognostic for the risk of biochemical recurrence and completely independent of the intermediate GG. Our results suggest that markers generated by computational proteomic profiling have the potential for clinical applications including integration into prostate cancer management.

2023-11-30 | PXD041005 | Pride

Risk adapted prevention strategies for colorectal cancer

Project description:Interventions: Group 1: Persons without family history of colorectal cancer: to fill out online-questionnaire Group 2: Persons with family history of colorectal cancer: to fill out online-questionnaire, take part in consultation regarding colorectal cancer prevention and donate the biosamples Primary outcome(s): The aims of the RaPS study are: 1. To provide the necessary empirical evidence for the design and implementation of efficient risk adapted CRC (colorectal cancer) screening strategies among the high risk group of people with family history of CRC. 2. To identify and evaluate novel biomarkers for noninvasive risk stratification and early detection of CRC and its precursors among people with family history of CRC. Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: prevention

| 2431112 | ecrin-mdr-crc

Foregut Microbiome and Risk of Gastric Intestinal Metaplasia, and Gastric Cancer Risk

Project description:Foregut Microbiome and Risk of Gastric Intestinal Metaplasia, and Gastric Cancer Risk

| PRJNA756700 | ENA

Foregut Microbiome and Risk of Gastric Intestinal Metaplasia, and Gastric Cancer Risk

Project description:Foregut Microbiome and Risk of Gastric Intestinal Metaplasia, and Gastric Cancer Risk

| PRJNA756701 | ENA